Having in mind the PLAC1 specificity as well as rapid internalization profile of the antibody upon engagement with its cell surface ligand in prostate cancer cells prompted us to address therapeutic potential of a drug-conjugated antibody. Here, PLAC1 is linked to prostate carcinoma.